Organisation paid for research Program year 2025 Source: CMS Open Payments

Lourdes Cardiology Services

Neither a doctor nor a teaching hospital

Research payments

$211,722

55 payments

Through program year 2025, Lourdes Cardiology Services is reported as receiving $211,722 in research payments, across 55 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,000 1
2024 Research $2,846 1
2023 Research $18,212 2
2022 Research $976 2
2021 Research $4,721 5
2020 Research $51,880 20
2019 Research $130,086 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $87,293 15 payments
  2. Pfizer Inc. $43,188 3 payments
  3. Abbott Laboratories $34,388 21 payments
  4. Novartis Pharmaceuticals Corporation $24,699 6 payments
  5. Merck Sharp & Dohme Corporation $10,114 8 payments
  6. AstraZeneca Pharmaceuticals LP $6,275 1 payment
  7. Tryton Medical, Inc. $5,765 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. FOURIER OLE (Ph 4) $43,922 6 payments
  2. A Phase 3 Randomized Doubleblind Placebocontrolled 26Week Multicenter Study With A 78Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo $43,188 3 payments
  3. Vesalius-Cv $32,032 2 payments
  4. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $24,699 6 payments
  5. Hemodynamic-GUIDEd Management of Heart Failure $13,768 4 payments
  6. Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) $10,505 4 payments
  7. A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA $10,114 8 payments
  8. Vesalius - CV $6,998 3 payments
  9. Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes $6,275 1 payment
  10. Post Approval Study $5,765 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Other $5,765 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record